Induction of functional bradykinin B1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment

Circulation

Volumn 105, Issue 5, 2002, Pages 627-632

  Marin Castaño, Maria E ^a   Schanstra, Joost P ^a   Neau, Eric ^a   Praddaude, Françoise ^a   Pecher, Christiane ^a   Ader, Jean Louis ^a   Girolami, Jean Pierre ^a   Bascands, Jean Loup ^a  

^a CHU RANGUEIL   (France)

Author keywords

Angiotensin converting enzyme; Blood pressure; Bradykinin; Kidney

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; MESSENGER RNA; PROSTAGLANDIN E2; RAMIPRIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; BLOOD PRESSURE REGULATION; CAROTID ARTERY; CONTROLLED STUDY; ENZYME ACTIVITY; HEART LEFT VENTRICLE; KNOCKOUT MOUSE; MALE; MOUSE; NEPHRON; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BRADYKININ; DINOPROSTONE; DRUG ADMINISTRATION SCHEDULE; ENZYME ACTIVATION; HYPOTENSION; KIDNEY; MALE; MICE; MICE, KNOCKOUT; NEPHRONS; ORGAN SPECIFICITY; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; RECEPTORS, ANGIOTENSIN; RECEPTORS, BRADYKININ; RNA, MESSENGER; TETRAZOLES; TIME;

EID: 0037022211     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc0502.102965     Document Type: Article

References (33)

1. Bioregulation of kinins: Kallikreins, kininogens, and kininases
2. Kallikreins and kinins
3. The B1-receptors for kinins
4. Angiotensin I converting enzyme and the changes in our concepts through the years
5. 1-receptors and the cardiovascular system: Regulation of expression and function
6. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
7. Effect of BK-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
8. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial: The losartan heart failure survival study ELITE II
9. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides
10. Angiotensin-converting enzyme inhibitors
11. 2-receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men
12. Bradykinin-mediated cardiovascular protective actions of ACE-inhibitors
13. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
14. Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect?
15. Kidney dysfunction: A sensitive predictor of cardiovascular risk
16. 1 receptor-mediated changes in renal hemodynamics during endotoxin-induced inflammation
17. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung
18. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons
19. Differential induction of functional B1-bradykinin receptors along the rat nephron in endotoxin induced inflammation
20. A rapid versatile method to synthesize internal standards for competitive PCR
21. Angiotensin-converting-enzyme inhibitors and expression of des-Arg9-BK (kinin B1) receptors in vivo
22. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects
23. Additive hypotensive effect of angiotensin-converting-enzyme inhibition and angiotensin-receptor antagonism in essential hypertension
24. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan And Lisinopril Microalbuminuria (CALM) study
25. Additive hypotensive and anti-albuminuric effects of angiotensin-converting-enzyme inhibition and angiotensin-receptor antagonism in diabetic spontaneously hypertensive rats
26. Add-on angiotensin receptor blockade with maximized ACE inhibition
27. Additive effects of combined angiotensin-converting-enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
28. The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-κB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts
29. Autoregulation of bradykinin receptors: Agonists in the presence of interleukin-1β shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts
30. Vasoactive potential of the B1 bradykinin receptor in normotension and hypertension
31. Renal vasoconstrictive effect of kinins mediated by BI-kinin receptors
32. Characterization of two polymorphic sites in the human kinin B1-receptor gene: Altered frequency of an allele in patients with a history of end-stage renal failure
33. Bradykinin B1-receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty